TIDMTRX

RNS Number : 5762H

Tissue Regenix Group PLC

04 December 2020

Tissue Regenix Group plc

Board changes

Leeds, 4 December 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group",) the regenerative medical devices company, announces its intention to appoint Brian Phillips and Trevor Phillips (no relation) as independent Non-Executive Directors of Tissue Regenix.

Brian Phillips is an entrepreneurial investment professional with over 25 years' experience. Brian is the current Principal of Ethos partners which he co-founded in 2018 to assist individuals in establishing a portfolio of assets under private equity investments. Prior to this, Brian was Chief Investment Officer at Greenhill Capital Partners Europe LLP where he was responsible for setting up their UK business (2006-2010) and Managing Director of LGV Capital (2000-2006). Brian holds a B.Acc from Glasgow University and qualified as a Chartered Accountant with KMPG.

Trevor Phillips is the current Chairman of the Board at NEPeSMO and has extensive experience in the UK and US in corporate development, M&A and operations in the pharmaceutical and life science industries including previously held positions as Executive Chairman of hVIVO (2017-2020), Chief Operating Officer for Vectura Group plc (2011-2017) and former CEO and COO of Critical Therapeutics, Inc. (2002-2008). Trevor holds a BSc, Microbiology from the University of Reading, a PhD, Microbial Biochemistry from Swansea University and an MBA from Henley Business School.

Both Brian and Trevor will be appointed to the board of Tissue Regenix following the completion of the necessary regulatory due diligence in accordance with the AIM Rules. Following appointment, Brian Phillips will Chair the Audit Committee and Trevor Phillips will Chair the Renumeration Committee.

Alongside this, after many years of service, Alan Miller and Randeep Grewal have notified the Board of their resignation as Non-Executive Directors with immediate effect.

Jonathan Glenn, Interim Chair of Tissue Regenix, commented: "As we focus on leveraging our operational capabilities and driving the commercialisation of our product pipelines, I am pleased to welcome Brian and Trevor to the Board who both bring a wealth of experience that will be crucial in shaping the future strategy and success of the Group. I would like to extend my thanks to Alan and Randeep who have been highly committed Board members and have supported the Group for many years."

For more Information:

 
 Tissue Regenix Group plc                     Tel: 0330 430 3073 
  Caitlin Pearson Head of Communications 
------------------------------------------  -------------------- 
 
 Stifel Nicolaus Europe Limited (Nominated   Tel: 0207 710 7600 
  Adviser and Broker) 
  Ben Maddison / Alex Price 
------------------------------------------  --------------------

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies(R), a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAFSESMLESSELE

(END) Dow Jones Newswires

December 04, 2020 02:00 ET (07:00 GMT)

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Tissue Regenix Charts.
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Tissue Regenix Charts.